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The migraine postdrome
An electronic diary study
ABSTRACT
Objective: To report migraine postdrome symptoms in patients who report nonheadache symp-
toms as part of their attacks.
Methods: A prospective daily electronic diary study was conducted over 3months in 120 patients
with migraine. Nonheadache symptoms before, during, and after headache were collected on
a daily basis. Visual analogue scales were used to capture the overall level of functioning and
the severity of the headache. The postdrome was defined as the time from resolution of trouble-
some headache to return to normal.
Results: Of 120 evaluable patients, 97 (81%) reported at least one nonheadache symptom in the
postdrome. Postdrome symptoms, in order of frequency, included feeling tired/weary and having
difficulty concentrating and stiff neck. Many patients also reported a mild residual head discom-
fort. In most attacks (93%), there was return to normal within 24 hours after spontaneous pain
resolved. There was no relationship between medication taken for the headache and the duration
of the postdrome. The severity of the migraine was not associated with the duration of the post-
drome. Overall state of health scores remained low during the postdrome.
Conclusion: Nonheadache symptoms in the postdrome were common and may contribute to the
distress and disability in the patients studied. Postdrome symptoms merit larger observational
studies and careful recording in clinical trials of acute and preventive migraine treatments.
Neurology® 2016;87:309–313
GLOSSARY
ICHD 5 International Classification of Headache Disorders.
Migraine is a common, disabling neurologic disorder characterized by a typically unilateral,
often throbbing headache with associated features. The migraine attack is typically divided into
4 nonobligatory phases: the premonitory phase, the aura, the headache phase, and the post-
drome. Nonheadache symptoms may start before the headache phase begins or during the pre-
monitory period,1 the headache phase, or the postdrome. These symptoms involve brain
activation of cortical and subcortical structures.2 Nonheadache symptoms may persist for 1 to
2 days after the headache has resolved in the postdrome or recovery phase.3 Postdromal symp-
toms, identified by retrospective recall of typical experiences, include tiredness, impaired con-
centration, and reduced mood.4
The postdrome, while disabling for many patients,3–6 has not been prospectively docu-
mented, and is not defined in the International Classification of Headache Disorders (ICHD).7
Electronic diaries, completed during and after migraine attacks, have many advantages for
studying nonheadache symptoms. Contemporaneous diary reporting reduces recall bias. The
electronic diary provides time-stamping so that investigators know when data were recorded.
The purpose of this study is to characterize nonheadache symptoms in persons with migraine
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reporting these. Descriptive data on postdro-
mal features may shed light on their mecha-
nisms and offer novel approaches to treating
and terminating headaches.
METHODS Migraine patients (n5 120) who claimed to expe-
rience nonheadache symptoms other than aura, nausea, vomiting,
photophobia, and phonophobia preheadache, in at least 2 of 3
migraine attacks, were recruited from 4 centers and enrolled in
a 3-month electronic diary study. The study was designed to
detail nonheadache features in all phases of the migraine attack.
The methods of this study have been previously described when
the premonitory data were presented.1
Standard protocol approvals, registrations, and patient
consents. The study was reviewed by each center’s ethics board
and patients gave written, informed consent.
Patients had between 2 and 8 migraines per month by the
ICHD-1 criteria, which are similar to ICHD-3-beta criteria.7
Participants eligible for analyses had to record data from at least
3 headache attacks.
Definition. The postdrome was defined as the time between
headache resolution and feeling completely back to normal. Head-
ache resolution was defined as cessation of troublesome headache.
Diaries. The diaries were programmed to alarm randomly once
daily during waking hours. Patients answered questions to capture
nonheadache symptoms before, during, and after the migraine
headache. Patients were encouraged to make voluntary entries when
they experienced nonheadache symptoms or were experiencing
a migraine attack. Diary entries could not be altered once confirmed
by the participant.
Analysis. Data were tabulated and descriptive statistics were cal-
culated using Excel (Microsoft, Redmond, WA). As an explor-
atory study, no power calculation was performed. Statistical
testing was carried out using a level of significance of p , 0.05
(SPSS 22; SPSS Inc., Chicago, IL).
RESULTS Of 120 recruited patients, 23 reported fewer
than 3 migraines during the study period and were
excluded from the analysis. Of the remaining 97, there
were 9 protocol violators: 1 did not usually experience
2–8 migraines per month, 5 recorded diary entries on
fewer than 80% of days, and 3 took excluded medica-
tions: flunarizine or valproate. Twelve patients withdrew
before the end of the study with diary fatigue, though all
had usable data with more than 3 migraine headaches in
the study period and were included in the analysis. A
total of 352 diary entries during the postdrome were
recorded: 160 recorded spontaneously by patients, 192
prompted by the electronic diary, and a further 421
afterwards. Data on a total of 773 migraine attacks with
postdromes out of a total 873 migraine attacks from 97
patients were recorded.
Overall nonheadache symptoms in the postdrome before
electronic diary use.Of the analyzed patients, 82 of 97
(85%) patients estimated before using the electronic
diary that they experienced nonheadache symptoms
after the headache resolved. Of these 82 patients,
54 (66%) estimated that they had nonheadache
postdrome symptoms in more than 90% of their
migraine attacks. The postdrome was estimated to
linger for at least a day in 49% of patients (table 1).
Postdrome symptoms recorded in the electronic diary.
Symptoms in the postdrome.We divided postdromal symp-
toms into 3 broad groups: cognitive/mood/energy, auto-
nomic, and gastrointestinal symptoms, as well as sensory
sensitivity. Being tired or weariness was the most com-
mon symptom, reported in 88% of postdromes. Other
frequently reported symptoms included difficulty with
concentration (56%) and stiff neck (42%). Typical
migraine attack symptoms of nausea, photophobia, and
phonophobia were also common (table 2). Mean quality
of life score, as measured on a visual analogue rating score,
was 57/100, compared to 51 in the premonitory phase,
33 during the headache phase, and 81 between attacks.
Time to recovery in the postdrome. There was a return
to normal within 6 hours of the end of the headache in
422 of 773 (54%) migraine attacks with a postdrome;
only 7% lasted more than 24 hours (table 3). Head-
ache severity did not predict length of the postdrome
(F3,5 5 3.2, p 5 0.25; table 3).
Effect of medications. The duration of the postdrome
did not vary significantly with the medication taken
to relieve the migraine headache or headache severity
(F2,5 5 6.8, p 5 0.08; table 3).
Difference in the relative frequency of recalled and
diary-based estimates of postdromal symptoms. In table 2,
we list the proportion of patients who report each
postdrome symptom at baseline and compare it with
the proportion who recorded those symptoms in the
electronic diaries. There is a striking underestimation
Table 1 Details of postdrome symptoms estimated
by patients before using the electronic
diary
No. (%)
After what proportion of migraine headaches
does the patient experience nonheadache
symptoms?
>90% 54 (66)
50%–90% 24 (29)
30%–50% 4 (5)
<30% 0 (0)
Total 82 (100)
NA 15
How long after the migraine headache has
resolved do these symptoms resolve?
Immediately 2 (2)
After a few hours 40 (49)
‡1 day 40 (49)
Total 82 (100)
NA 15
Abbreviation: NA 5 not available.
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of the frequency of neck stiffness and sensitivity to
light and noise.
DISCUSSION We have shown in this study that post-
drome symptoms are a frequent feature of migraine at-
tacks in patients who report nonheadache symptoms,
with more than 80% of attacks being followed by such
symptoms. The data show that prevalence of these
symptoms is underreported using recall at baseline rel-
ative to contemporaneous measurement using daily
e-diaries. When identified, patients acknowledge the
disabling nature of premonitory symptoms. Interest-
ingly, the treatment type and attack severity did not
seem to influence the duration of the postdrome. Data
from this report, when combined with an earlier report
from this cohort on the premonitory phase,1 reveals
that some symptoms begin in the premonitory phase
and extend through the postdrome. Given the reduced
quality of life associated with these symptoms, and the
importance of better understanding of attack termina-
tion, the postdrome deserves more systematic study.
Our data are in accordance with reported retro-
spective studies. In one study, 47 of 50 patients
remained symptomatic after their headache had
ended.4 In that study, the most frequent symptoms
were changes in mood (72%), muscular weakness
(54%), and reduced appetite. In another study, 78
out of 100 unselected migraineurs reported resolution
symptoms in a given attack5; most common were
asthenia (55%), tiredness (46%), somnolence
(29%), and concentration difficulties (28%). A large
clinic-based sample found that 562 of 827 patients
retrospectively reported postdromes; in 88%, they
lasted less than 24 hours. Tiredness was the most
common symptom in 72%.3 In a US study designed
to test a postdrome instrument, patients (n 5 32)
again reported tiredness, nausea, and concentration
difficulties most commonly.6
Most studies of postdromes have methodologic
limitations. Retrospective studies are open to recall
bias. The most recently experienced or severe post-
dromal symptoms may be selectively recalled and
other features may be forgotten. Paper diaries may
be retrospectively completed at times remote from
the headache attack. In contrast, our study recorded
the postdrome symptoms on a prospective basis,
using a time-stamped electronic diary that could
not be modified once data had been entered. Thus,
we can be confident that features were recorded at
the stated time, facilitating the assessment of individ-
ual attacks.
Characterization of postdromal nonheadache
symptoms may lead us to a better understanding of
the pathophysiology of the migraine process. Migraine
pathophysiology involves dysfunction of diencephalic
and brainstem centers thought to be involved in pain
processing and other sensory modalities modulation.8
Pontine and midbrain structures have altered function
during migraine attacks and after remissions that occur
with triptans. Although triptans effectively treat
migraine headache, they do not alter the fundamental
brainstem mechanisms responsible for migraine gener-
ation.8 This may explain why although head pain is
ameliorated by triptans, nonheadache symptoms
persist.
There was little difference in postdrome duration
between treated and untreated attacks. However, this
was not a controlled study and no firm conclusion on
the effect of medication on the postdrome can be
reached. We did not analyze the time taken to recover
in the postdrome after taking triptans compared to
other medication. The effect of triptans on the post-
drome has never been studied systematically and this
is potentially an unexplored therapeutic area that
would be of benefit to migraineurs.
Our study has several limitations. While we are
confident that the symptoms were present during
the postdromal phase, their background prevalence
was not recorded, as we primarily recruited patients
with premonitory symptoms. There are little data
on the prevalence of interictal symptoms in migrai-
neurs. Fatigue is reported in up to 70% of patients
Table 2 Relative frequency of postdromal symptoms reported at baseline and
recorded prospectively in the electronic diary study
Nonheadache feature
Percent of patients
who recalled each
postdromal symptom
at baseline (n 5 83)
Percent of attacks
prospectively
reporting each
postdromal symptom
during the e-diary
study (n 5 425)
Tired/weary 75 88
Difficulty with concentration 67 56
Stiff neck 16 42
Light sensitive 13 36
Intolerant/irritable 22 29
Dizziness 10 19
Yawning 15 14
Pale face 18 21
Noise sensitive 12 32
Hunger/food craving 15 15
Thirst 13 32
Emotional 13 24
Difficulty with thoughts 15 33
Constipation 4 7
Frequent urination 7 21
Nausea/vomiting 6 15
Difficulty reading or writing 10 17
Difficulty with speech 5 9
Other 32 44
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with chronic headache9 and severe headache; sleep
difficulty (60%) and nausea/indigestion (55%) are
also common.10 We only studied patients selected
from headache centers based on their nonheadache
symptoms, limiting the generalizability of the conclu-
sions. Population-based studies are needed to deter-
mine prevalence. Most symptoms were estimated
reasonably accurately at baseline compared to those
recorded in the diaries. We have not correlated the
symptoms to medicine use, and conceivably some
may be treatment effects. The underestimation of
neck stiffness, light sensitivity, and noise sensitivity
may occur because these symptoms are prominent
during the headache phase and patients do not usu-
ally perceive them to be a problem after the headache.
The persistence of nonheadache symptoms
throughout all phases of the migraine attack sup-
ports the hypothesis of persistent brain changes in
the attack. An altered functional state may develop
during the premonitory period and persist through-
out the headache phase into the postdrome. The
description of these symptoms opens the new chal-
lenge to pursue their biology and eventually better
manage migraine.
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